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ABSTRACT (249/300 words)  
Objective: Typically, migraine prevention trials focus on reducing migraine days. This narrow focus 
may not capture all that is important to people with migraine. Inconsistency in outcome selection 
across trials limits the potential for data pooling and evidence synthesis. In response, we describe 
the development of core outcome set for migraine (COSMIG). 
Design: A two-stage approach sought to achieve international, multi-stakeholder consensus on both 
the core domain set (CDS) and core measurement set (CMS). Following construction of a 
comprehensive list of outcomes, expert panellists (patients, healthcare professionals and 
researchers) completed a three-round electronic-Delphi study to support a reduction and 
prioritisation of core domains and outcomes. Participants in a consensus meeting finalised the core 
domains and methods of assessment. All stages were overseen by an international core team, 
including patient research partners.  
Results: There was good representation of patients (episodic (n=34) and chronic migraine (n=42)) 
and healthcare professionals (n=33) with high response and retention rates. The initial list of 
domains and outcomes was reduced from >50 to seven core domains for consideration in the 
consensus meeting, during which a two-domain core outcome set was agreed.  
Conclusion: International and multi-stakeholder consensus emerged to describe a two-domain core 
outcome set for reporting research on preventive interventions for chronic and episodic migraine: 
migraine-specific pain and migraine-specific quality of life. Intensity of migraine-pain assessed with 
an 11-point numerical rating scale and the frequency as the number of headache/migraine days over 
a specified time-period. Migraine-specific quality of life assessed using the Migraine Functional 
Impact Questionnaire.  
Strengths and limitations of this study:  
 The research process and validity of results are strengthened by the co-collaboration with 
patient research partners throughout all stages of the research.  
 A bespoke grading system to support the prioritisation of outcome domains between 
stakeholder groups (expert panels) is described.
 International, multi-stakeholder participation – patients, researchers, and a range of health 
professionals - in the on-line Delphi survey. 
 Expert panel representation in the Delphi survey was largely from Europe and North 
America. 
 The majority of participants in the face-to-face consensus meeting were from the UK. 
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BACKGROUND  
International guidelines for the conduct of preventive studies for both episodic and chronic migraine 
specify that the primary outcome should be focussed on migraine days, or for chronic migraine on 
moderate to severe headache days 1. Reviews of clinical trials of populations with chronic migraine 
and episodic migraine have identified substantial inconsistencies in outcomes reporting alongside 
often poorly defined outcomes 2, 3. An important impact of these inconsistencies is to limit the 
potential for robust meta-analyses 4 5. For example, a 2015 meta-analysis of drugs for the 
prophylaxis of migraine by Jackson et al 6 did not include data from the largest and most robust trial 
of topiramate for chronic migraine (n=307) that found a mean difference of 1.7 migraine/migrainous 
days per 28 days after 12 weeks 7. The reviewers meta-analysed the data from two much smaller 
(n=32 & n=50), low quality studies, and reported an effect size of 8.4 headache days, the outcome 
specified for the meta-analyses, after 12 weeks. Data that cannot be interpreted or utilised can 
result in unacceptable and unethical research waste. There is also potential for selective outcomes 
reporting and associated reporting bias if consistent outcomes are not pre-specified 8, 9.  
Improved consistency, accountability and transparency in outcome reporting can be achieved by 
using a Core Outcome Set (COS); a small, standardised group of outcomes that should be measured 
and reported, as a minimum, in all effectiveness trials for a specific health area 10-12.  
Current international guidelines for conduct of prevention studies in episodic or chronic migraine 
have not developed outcome reporting recommendations in line with current best practice 
1, 13. Notably, patient input is markedly absent from these guidelines.   
We describe here the development of a multiple-stakeholder, internationally endorsed, consensus-
based COS applicable to preventative intervention trials and research studies in adults with episodic 
or chronic MIGraine (COSMIG). 
Methods 
Two key stages in core outcome set development are described (figure 1) 14:  
Stage 1) Defining the core domain set: WHAT to measure; i.e., the minimum number of 
health domains that should be assessed. A domain describes the concept or ‘aspect of health or a 
health condition that needs to be measured to appropriately assess the effects of a health 
intervention’ 14. 
Stage 2) Recommending the core measurement set: HOW to measure, i.e., the minimum set 
of assessment methods that adequately correspond to the core domain set. 
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We prospectively registered COSMIG with the Core Outcomes Measures in Effectiveness Trials 
(COMET) initiative [http://www.comet-initiative.org/studies/details/953]. Ethical approval was 
gained from Warwick Medical School Biomedical and Scientific Research Ethics Committee REGO-
2017-1921.  
Patient and public involvement 
Following good practice guidance [https://www.invo.org.uk/posttyperesource/before-you-start-
involving-people/; 15 we worked collaboratively with our patient research partners, who all had 
experience of chronic or episodic migraine, throughout all stages of the research. 
The COSMIG core group consisted of clinicians with expertise in headaches and migraine (MM,MU, 
BD), including two international members (RL,RJ), research scientists with expertise in clinical trials, 
Delphi technique, health measurement and qualitative research (MU,KH,RF,RP,SP,VN,SP,KS) and 
patient research partners (GP,BB,LM). Regular meetings were held between all group members to 
discuss the methodology for the Delphi study and the subsequent consensus meeting. The group 
met specifically between each Delphi round, to discuss results, confirm feedback and format for 
subsequent rounds. 
Stage 1 Core Domain Set 
Stage 1.1: Developing a comprehensive domain list 
We first identified potential domains from systematic reviews 2, 3 and qualitative research 16. 
Domains were written in plain English as on-line questionnaires: one questionnaire contained 
domains for episodic headache, and one for chronic headache. Questionnaires were piloted with the 
core team and researchers naïve to the study (n=12). 
Stage 1.2: International modified-Delphi process  
Our primary goal for our Delphi study was to refine and prioritise domains. The Delphi process seeks 
to establish consensus between a panel of experts following a structured process of questionnaire 
completion and systematic feedback.17, 18 The panels are not intended to be representative of all 
headache specialists or people with migraine (as is the case when sampling from a definable 
population). We defined two expert panels external to the core research team: one comprised of 
expert patients with a target of up to 50 with chronic migraine (CM) and 50 with episodic migraine 
(EM); and a second panel (also up to 50) comprised of healthcare professionals and researchers, who 
were representative of their professions and well-placed to implement study findings19.
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Professionals included neurologists, nurse specialists, general practitioners, allied health 
professionals, researchers, and measurement experts. We sought consensus between experts on the 
core domain set.  
 Patients: We asked 13 national/international organisations to advertise the study on their 
social media platforms. Interested participants (≥18-years old) contacted the research team. We 
asked participants to self-diagnose/classify their migraines as episodic or chronic migraine. Patient 
participants completed episodic or chronic migraine questionnaires depending on their self-
diagnosis. 
Professionals: We invited national and international healthcare professionals (neurologists, 
GPs, nurses, psychologists, pharmacists, allied health professionals) and researchers (trialists, 
reviewers, health economists, measurement experts) involved in headache research identified 
through professional societies and from published research to participate. They were asked to 
complete both questionnaires. 
The Delphi process had three sequential rounds with participants completing each prior round 
eligible to complete the next. The Delphi study administration and hosting of the on-line 
questionnaires was managed by Clinvivo Ltd. 
Round 1 Participants rated the relative importance of each domain for inclusion in future research 
studies of chronic or episodic headache using a nine point numerical rating scale (range 1 to 3 ‘Not 
at all important’, 4 to 6 ‘Uncertain’, and 7 to 9 ‘Very important’). Participants could elaborate on 
their decisions by providing additional qualitative comment and/or provide additional domains for 
consideration and rating in subsequent rounds. Informed by an approach described by Orbai et al. 
(2017) 20, we devised a bespoke grading system to illustrate where consensus was achieved and to 
indicate more easily where participants in each panel disagreed in their judgement (Appendix Table 
1). An a priori decision rule determined that only those outcome domains judged most favourably by 
one or both panels (patients and professionals) would be included in round two. That is, domains 
were included in round 2 if in both panels the median rating was 9 (‘A**’), or if in both panels ≥70% 
rated a domain ≥7 (‘A*’). If in both panels the median domain rating was is ≥7 (‘A’), or the median 
rating for a domain was is ≥7 in just one panel (‘B’), the domain could be included in round 2 if either 
panel achieved a median score of 9 or qualitative evidence supported further consideration. 
Round 2 In round two we focused more specifically on migraine-specific (e.g. nausea and 
photophobia), rather than headache-specific, domains. Responses to round one were summarised 
and anonymous feedback provided. Participants all received their own score for each domain, and 
the group median scores. Further prioritisation was achieved by inviting participants to ‘spend 
7 
points’ (up to a maximum of 70) to illustrate how strongly they felt that a domain should be 
prioritised for inclusion in the core domain set; a maximum of 10 points could be allocated to any 
one outcome domain (11-point scale, 0 ‘Not a priority’ to 10 ‘Absolute priority’). To ensure that sub-
panel differences were considered, and any discrepancies highlighted, the results from both panels 
were considered both separately and combined: the top 10 and top 50% of prioritised domains were 
discussed between COSMIG core team members, informing the maintenance of, or, where the 
concepts of health were similar, grouping of domains into a single ‘meaningful’ domain.  
Round 3 Responses to round two were summarised, highlighting the top 50% of prioritised domains 
and between-panel discrepancies. For those domains prioritised highly by just one panel (top 50%), 
participants were asked to reconsider if they should be included in the priority listing. If more than 
70% of respondents selected ‘yes’, the domain was included. Finally, participants were asked to 
indicate by means of a dichotomous response if they: a) were happy with the grouping of prioritised 
domains; b) were happy with the proposed ‘meaningful’ domain and definition; and c) had 
additional comments. The frequency distribution of responses was calculated. Results from both 
sub-panels were again considered separately and combined. 
Stage 2: Core Measurement Set 
International expert panel face-to-face meeting 
The purpose of the one-day meeting was to discuss the core domain set developed in our modified 
Delphi study, agree the core measurement set, and recommend the core outcome set. Importantly, 
participants were to consider that whilst a domain may be considered important, if an acceptable 
approach to measurement is not available, it is not appropriate to include the domain in a core 
outcome set.  
We invited professionals from Europe and patients from the UK who had taken part in our Delphi 
study. Participants received an information pack with meeting objectives and domain/measurement 
information ahead of the meeting. Where existing consensus for potential measures was not 
available, the COSMIG core team reviewed key data sources for guidance and evidence of 
measurement quality, acceptability and feasibility for use in preventive studies of episodic or chronic 
migraine:21
 Migraine / headache:  
o Review of patient-reported outcome measures (PROMS)2
o International Headache Society guidelines 1, 13, 22
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o National Institute for Neurological Disorders Common Data Elements – 
Headache (preventative treatment)23
 Chronic Pain and core outcome set development 
o Initiative on Methods, Measurement and Pain Assessment in Clinical Trials24-
26
o Outcome Measures in Rheumatology and Clinical Trials group 27
The meeting started with an overview of the results of the Delphi process, prioritised domains, and 
the evidence-base underpinning potential methods of assessment. Participants were asked to 
consider three options when determining domain ‘placement’ within the final core outcome set 20:  
i) Core ‘inner’ circle: domain is unambiguous with an acceptable method of 
assessment;  
ii) Middle circle: domain is important, but not feasible for all preventative trials and 
research studies;  
iii) Outer circle: domain is important but requires further study (research agenda) – e.g. 
lacks conceptual clarity or method of assessment. 
Semi-structured, small-group discussions with a mix of patients, healthcare professionals/ 
researchers and members of the core research team (including patient partners) ensued, covering 
each prioritised domain. Two facilitators each supported two rounds of discussion per domain. 
Outcome domains and methods of assessment were reviewed in terms of importance, quality, 
acceptability, and feasibility. Facilitators supported participant contribution and shared findings 
between groups to stimulate discussion. Following each small-group discussion, participants, with 
the exception of the core research team, were asked to indicate anonymously (paper-based 
questionnaire) their preference for domain inclusion (yes/no/don’t know) and method of 
assessment (selecting one option from a short-list) in the core outcome set; an a priori definition of 
agreement required ≥ 70% of panellists to agree.  
Next, small group discussions and results were presented to the whole group. Where there was 
agreement, no further discussion was required. Subsequent discussion focused on where further 
refinement was required. Finally, participants voted electronically to confirm domain placement in 
the COS (inner/middle/outer/out) and method of assessment. Proceedings were captured in the 
form of detailed written records and the outcomes of voting.  
Results 
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Stage 1 Core Domain Set 
Stage 1.1: Developing a comprehensive domain list 
A total of 57 (episodic) and 58 (chronic) domains were included in the questionnaire, grouped across 
four areas: symptoms (17), life impact (27 episodic / 28 chronic), treatment effectiveness/ financial 
impact (10) and complications (2). Piloting informed minor language modifications.  Fifty-seven of 
the domains of interest were included for both episodic and chronic migraine.
Stage 1.2: International modified-Delphi process  
Round one 
Sub-panel 1 (patients) Two organisations advertised the study (Migraine Association, Ireland; 
National Migraine Centre, UK). Almost 80% (76/96) of patients who expressed an interest in taking 
part in the study completed the first questionnaire (42/53 CM (79%); 34/43 EM (79%)). Most were 
female (CM 40/53 (73%); EM 29/43 (66%)) and aged between 36-45 (CM 41%) and 56-65 years (EM 
32%) (range 18 to >66 years). Most were from the UK (57%), followed by the US (19%), Ireland 
(14%), Canada (2%), and the rest of Europe (Denmark (2%), France (5%)).  
Sub-panel 2 (professionals) From a total of 198 international healthcare professionals/researchers 
invited to participate, 64 agreed. Nearly half (31/64 (48%)) joined the panel to complete the episodic 
migraine questionnaire; slightly more (33/64 (52%)) completed the chronic migraine questionnaires.  
Most were from the UK 14/33 (42%), with participants from the US  5/33 (15%), Europe (Belgium 
1/33 (3%), Germany 2/33 (6%), Italy 1/33 (3%), Netherlands 1/33 (3%), Portugal 1/33 (3%), Serbia 
1/33 (3%), Spain 2/33 (6%)) and Turkey 1/33 (3%)), the Russian Federation 1/33 (3%), South Africa 
1/33 (3%) and Thailand 1/33 (3%). Professionals included neurologists, nurse specialists, general 
practitioner, allied health professionals, researchers, and measurement experts (Appendix Table 2). 
In total, 75 (64%) and 65 (61%) panellists completed round 1 chronic and episodic migraine 
questionnaires, respectively. 
Most domains were rated as ‘important’, with few between panel discrepancies. Implementation of 
the a priori decision rule (Appendix Table 1) supported a 50% reduction in domains, with the 
prioritisation of 18/57 (episodic) and 24/58 (chronic) domains (Table 1). 
Table 1. Delphi Round 1 shortlisted domains by voting prioritisation and agreement between panels 
Domain EPISODIC MIGRAINE  CHRONIC MIGRAINE 
Evidence supporting inclusion in Round 2 Delphi 
10 
Section 1: Life impact – symptoms associated 









Cognitive function – difficulty concentrating, 
ability to ‘think clearly’ or to remember things
(A) Yes A* 
Increased sensitivities – to light, sound, smell, 
touch
A* A* 
Pain associated with headache – experience an 
unpleasant physical sensation that aches or hurts
A** A* 
Duration of pain associated with a headache A** A* 
Frequency of pain associated with a headache A** A* 
Severity  / intensity of pain associated with a 
headache
A** A* 
Physical fatigue – experiencing physical fatigue, 
tiredness, lacking in energy, feeling physically 
exhausted 
(A) Yes A* 
Sleep quality – being able to have a restful sleep (A) A* 
Vomiting and/or feelings of nausea A* (A) 
Anxiety – concerned, worried, fearful or anxious (A) Yes (A) Yes 
Depressive mood – feeling sad, feeling down, 
feeling sorry for oneself or feeling depressed 
(A) Yes (A) No 
Section 2: Life impact – functioning, activities 
and general wellbeing 
Activities of daily life 
Being able to carry out usual tasks or daily 
activities inside or outside the home (not related 
to paid employment) that support an 
independent lifestyle – such as tidying one’s 
home, walking short distances, managing 
finance, driving, using technology 
(A) A* 




Feelings of isolation – feeling isolated, reduced 
social interactions 
(B) Yes (A) Yes 
Self-worth – feeling like a burden to others; can 
include feeling valued or helpless, accepted or 
rejected; feelings of self-esteem 
(B) Yes (A) Yes 
Stress – feelings of distress, frustration or 
irritation 
A* (A) Yes 
Work/Education 
Being able to carry out activities related to work
(paid or unpaid) / study to an acceptable or usual 
standard  
A* A** 




Social life – relationships with colleagues or 
peers 
A* 
Family roles – being able to provide usual care 
and support for family and close friends  
(A) Yes (A) Yes 
Participation in social or leisure activities – 
ability to participate in social or leisure activities 
(A) Yes (A) Yes 
Overall health – an individual’s general health 
status; the ability to live a ‘normal ‘ life 
A* A* 
Self-management – ability to effectively 
decrease/ minimise / control the impact of 




Unpredictability of a migraine – uncertainty of 
being symptom-free or able to engage in 
activities 
A* No (A)  Yes 
Trigger factors – ability to avoid / manage 
migraine trigger factors 
(B) Yes No 
Section 3: Treatment effectiveness and financial 
impact 
Satisfaction with treatment A* A* 
Confidence in treatment A* A* 
Consistency of treatment effect A* A* 
Medication use – the type (potency) and dose 
(how much) medication taken when 
experiencing a migraine or headache 
A* A* 
Medication use – the type (potency) and dose 
(how much) medication taken to prevent a 
migraine or headache 
A* A* 
Financial impact – the economic cost associated 
with migraine treatment (to the individual (out 
of pocket expenses)) and healthcare systems) 
(A) A* 
Use of healthcare resources in response to 
migraine 
(A) A* 
Section 4: Complications (Adverse Events) 
Treatment side effects – experiencing 
undesirable secondary effects from taking 
medications for migraine 
A* A** 
Mortality (death) (A) A** 
Included in Round 2 due to importance scores 
(A** or A*) 
18 24 
Included in Round 2 due to qualitative feedback 9 7 
New outcomes added due to qualitative 
feedback 
0 0 
TOTAL number of outcomes for inclusion in 
Round 2 
27 31 
Footnote: Each outcome was assigned to one of six categories reflecting levels of agreement: outcomes classified A** and 
A* would be included in round 2. 
 A** if in both sub-panels the median rating is 9 
 A* if in both sub-panels ≥70% rate an outcome ≥7 
 (A) if in both sub-panels the median outcome rating is ≥7 
 (B) if the median rating for an outcome is ≥7 in only one sub-panel 
Qualitative feedback informed further consideration of 10 domains (9 episodic, 7 chronic) not 
achieving the proposed benchmark. No ‘new’ domains were proposed.  
Round two 
Round two questionnaires contained 27 (episodic) and 31 (chronic) domains (Table 1). Round two 
was completed by 23/33 (70%) and 29/31 (93%) health professionals and 33/42 (79%) and 25/34 
12 
(74%) patients for chronic and episodic migraine, respectively (totalling 54 episodic (83%) and 56 
chronic (75%) migraine questionnaires completed). 
When prioritised according to the top 10 and top 50% of domains, several overriding ‘meaningful’ 
domains could be described (Tables 2 a-b); six of which were common to both episodic and chronic 
migraine: pain, usual activities, cognition, adverse events, overall health, associated symptoms. 
Respondents to the episodic migraine questionnaire also prioritised self-management, whilst 
medication use was prioritised by chronic migraine respondents.  
Table 2a. Delphi Round 2. Results of domain prioritisation for Episodic Migraine (combined panels 
n=27)** 
Rank* Proposed ‘merged’ domain and 
definition 
Top 10/27 prioritised 
domains 
Top 50% of prioritised 
domains                              
(rank 1 to 13/27 inclusive) 
Lower 50% of prioritised 
domains                    (rank 
14 to 27 inclusive) 
1 Pain 
- Experience of an 
unpleasant sensation 
that aches or hurts in 
the head; the 
frequency, severity 
and duration of this 
pain is important 
Pain associated with 
Migraine – experience of an 
unpleasant sensation that 
aches or hurts (1/27) 
Frequency of pain 
associated with a migraine 
(2/27) 
Severity or intensity of pain 
associated with a migraine 
(3/27) 
Duration of pain associated 
with a migraine (4/27) 
2 Usual activities
- Being able to carry 
out usual activities 
(including paid or 
unpaid work, study, 
domestic chores, care 
or support for family 
or close friends) to an 
acceptable or usual 
standard 
- Being able to 
participate in, or 
commit to, usual 
activities 
Being able to carry out 
activities related to work
(paid or unpaid) or study to 
an acceptable or usual 
standard (5/27) 
Family roles – able to 
provide usual care or 
support for family or close 
friends, including ability to 
commit activities (11/27) 
Needing to take time-off 
work (paid or unpaid) or 
study (13/27) 
Participation in social or 
leisure activities – ability 
to participate in, or 
commit to, social or 




to ‘think clearly’, or 
to remember things 
Cognitive function –
difficulty concentrating, 
ability to think ‘clearly’ or to 
remember things (6/27) 
4 Adverse events Treatment side-effects –
experiencing undesired 
secondary effects from 
taking medications for 
migraine (7/27) 
13 
5 Overall health An individual’s general 
health status; the ability to 
‘live a normal life’ (8/27) 
6 Self-management Trigger factors – the ability 
to avoid / manage migraine 
trigger factors (9/27) 
Self-management – ability 
to effectively decrease / 
minimise/ control the 
impact of migraine on 
oneself (e.g. 
pharmaceutical, diet, 
lifestyle choices etc) 
(11/27) 
Unpredictability of a 
migraine – uncertainty of 
being symptom free or 
able to engage in activities 
(17/27) 
** prioritised in top 10 
(10/27) by patients 
7 Associated symptoms Increased sensitivities – to 
light, sound, smell or touch 
(10/27) 
Vomiting and/ or feelings 
of nausea (15/27) 
** prioritised in top 10 
(8/27) by HCPs 
Physical fatigue –
experiencing physical 
fatigue, tiredness, lacking 
in energy, feeling 
physically exhausted 
(18/27) 
** prioritised in top 50% 
(11/27) by patients 
8 Medication use Satisfaction with 
treatment (14/27) 
** prioritised in top 10 
(9/27) by HCPs 
The type (potency) and 
dose (how much) of a 
medication taken when 
experiencing a migraine 
(16/27) 
** prioritised in top 50% 
(11/27) by HCPs 
The type (potency) and 
dose (how much) of a 
medication taken to 
prevent a migraine 
(21/27) 
Consistency in treatment 
(23/27) 
Confidence in treatment 
(25/27) 
9 Emotional well-being Anxiety (19/27)
Depression (19/27)
** prioritised in top 50% 






*Top 7 grouped domains – informed by top 10 and top 50% of prioritised domains (13/27). 
** 6 domains prioritised differently between the two panels; considered further in Round 3. 
Table 2b.  Delphi Round 2. Results of domain prioritisation for Chronic Migraine (combined panels 
n=31)** 
Rank* Domain and definition Top 10/31 prioritised 
domains 
Top 50% of prioritised 
domains                             
(rank 1 to 15/31 
inclusive) 
Lower 50% of prioritised 
domains                       (rank 
16 to 31 inclusive) 
1 Pain 
- Experience of an 
unpleasant sensation 
that aches or hurts in 
the head; the 
frequency, severity 
and duration of this 
pain is important 
Severity or intensity of pain 
associated with a migraine 
(1/31) 
Pain associated with 
Migraine – experience of an 
unpleasant sensation that 
aches or hurts (2/31) 
Frequency of pain associated 
with a migraine (3/31) 
Duration of pain associated 
with a migraine (4/31) 
2 Usual activities
- Being able to carry out 
usual activities 
(including paid or 
unpaid work, study, 
domestic chores, care 
or support for family 
or close friends) to an 
acceptable or usual 
standard 
- Being able to 
participate in, or 
commit to, usual 
activities 
Being able to carry out usual 
tasks or daily activities inside 
or outside the home (not 
related to paid employment) 
that support an independent 
lifestyle – such as tidying 
one’s home, walking short 
distances, managing finance, 
driving, usual technology 
(instrumental activities of 
daily life) (5/31) 
Being able to carry out 
activities related to work 
(paid or unpaid) or study to 
an acceptable or usual 
standard (6/31) 
Needing to take time-off 
work (paid or unpaid) or 
study (11/31) 
Family roles – able to 
provide usual care or 
support for family or close 
friends, including ability to 
commit activities (19/31) 
Participation in social or 
leisure activities – ability to 
participate in, or commit 









ability to think ‘clearly’ or to 
remember things (7/27) 
4 Adverse events Treatment side-effects –
experiencing undesired 
15 
secondary effects from 
taking medications for 
migraine (8/31) 
Mortality (death) (26/31)
** prioritised in top 50% 
(15/31) by HCPs 
5 Associated symptoms Increased sensitivities – to 




fatigue, tiredness, lacking in 
energy, feeling physically 
exhausted (10/31) 
Sleep quality – being 
able to have a restful 
sleep (14/31) 
Needing to rest or lie 
down because of a 
headache (15/31) 
6 Medication use Satisfaction with 
treatment (12/31) 
The type (potency) and 
dose (how much) of a 
medication taken to 
prevent a migraine (21/31) 
Consistency in treatment 
effect (23/31) 
The type (potency) and 
dose (how much) of a 
medication taken during a 
migraine (24/31) 
Confidence in treatment 
(28/31) 
7 Overall health An individual’s general 
health status; the ability 
to ‘live a normal life’ 
(13/31) 
8 Emotional well-being Stress – feelings of distress, 
frustration or irritation 
(16/31) 
** prioritised in top 10 
(10/31) by HCPs 
Anxiety – concerned, 
worried, fearful or anxious 
(20/31) 
Self-worth – feeling like a 
burden to others; can 
include feeling valued or 
helpless; accepted or 
rejected; feelings of self-
esteem (28/31) 
Feelings of isolation –
feeling isolated; reduced 
social interactions  (29/31) 
Social role – relationship 
with work colleagues or 
peers (31/31) 
9 Self-management Self-management – ability 
to effectively decrease / 
minimise/ control the 




lifestyle choices etc) 
(17/31) 
Unpredictability of a 
migraine – uncertainty of 
being symptom free or able 
to engage in activities 
(18/31) 
** prioritised in top 50% 
(14/31) by patients 
10 Financial impact Economic cost associated 
with treatment for 
headache (to the individual 
(out-of-pocket expenses) 
and healthcare system) 
(25/31) 
Use of healthcare resources 
in response to headache 
(30/31) 
Footnote: 
* Top 5 grouped domains – informed by top 10 prioritised domains. Top 7 grouped domains – informed by top 13 and top 
50% of prioritised domains (15/31). 
** 3 domains prioritised differently between the two panels; considered further in Round 3. 
Sub-panel discrepancies for both episodic and chronic migraine included patients’ prioritisation of 
overall health, physical fatigue, unpredictability, and self-management. Patients with episodic 
migraine also prioritised emotional wellbeing. Although awarded fewer points, people with chronic 
migraine prioritised the importance of social role and emotional wellbeing. In contrast, healthcare 
professionals prioritised treatment satisfaction, treatment side-effects and vomiting/ nausea for 
episodic migraine, and mortality and stress for chronic migraine. 
Round three 
Round three was completed by 23/23 (100%) and 21/29 (72%) health professionals, and 29/33 (88%) 
and 23/25 (92%) patients for chronic and episodic migraine, respectively (totalling 52/56 (93%) for 
chronic migraine and 44/54 EM (81%) for episodic migraine.  Six and three domain discrepancies 
(top 10 or top 50% for one sub-panel only) were considered for episodic migraine (treatment 
satisfaction; vomiting/ feelings of nausea; medication taken during a migraine; unpredictability; 
physical fatigue; depressive mood) and chronic migraine (stress; mortality; unpredictability), 
respectively (Appendix Table 3). 
The seven domains for episodic migraine were retained (>76% across sub-panels; >84% combined) 
(Table 3) and a new domain ‘Treatment Satisfaction’ proposed (>70% healthcare professionals; 68% 
combined) (Appendix Table 3). Voting on sub-panel discrepancies further supported the inclusion of 
vomiting/feelings of nausea, physical fatigue, and depressive mood within the developing core 
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domain set for episodic migraine (Appendix Table 3).  Qualitative feedback in the questionnaire 
supported a more positive re-phrasing of the concept of self-management. 
Table 3. Delphi Round 3: results of voting for domains for episodic and chronic migraine  
Proposed CORE DOMAINS for EM and CM






(informed by Round 2)
Proposed ‘Meaningful 
Domain’ and definition                                                              
(bold text informed by R3 
qualitative feedback)
Q Patient                           
(n=23) 










 Pain associated 
with migraine – 
an unpleasant 
sensation that 
aches or hurts 
 Frequency of 
pain associated 
with migraine 
 Severity or 
intensity of pain 
associated with 
migraine 




- Experience of an 
unpleasant 
sensation in the 
head that aches 




- the components 
of frequency, 
severity and 
duration of pain 
are all important 
Qualitative feedback 
supported the addition of: 
- unpleasant 
sensation in the 

















 An individual’s 
health status; 
the ability to live 
a ‘normal’ life 
OVERALL HEALTH 
- An individual’s 
health status; 
the ability to live 
a ‘normal’ life 
Qualitative feedback 
challenged the concept or 
‘normal life’ and the lack of 
clarity re a focus on 
migraine-specific or 
general quality of life. To 
















 Being able to 
carry out 
activities related 
to work (paid or 
unpaid) or study
to an acceptable 
or usual 
standard 
 Family roles- 
able to provide 
usual care or 
support for 




- Being able to 
carry out usual 
activities 
(including paid 
or unpaid work, 
study, domestic 
chores, family or 
leisure activities, 
care or support 
for family or 
close friends) to 
an acceptable or 
usual standard 
- Being able to 



















 Need to take 
time-off work 
(paid or unpaid) 
or study 
 Being able to 
carry out usual 
tasks or daily 
activities inside 




that support an 
independent 
lifestyle – such 







commit to usual 
activities 
Qualitative feedback 
supported the importance 
of including 
‘unpredictability’ in the 
definition: 
- Being able to 
plan, commit to, 
or participate in 
usual activities, 
including work, 
usual social or 
caring roles (due 
to the 
unpredictability 





ability to think 










supported the addition of: 
- difficulty with 
communication 
(word finding, 


































supported adoption of the 
CTCAE standardised 












may or may not 
be considered 





















sensitivities – to 
light, sound, 
smell or touch 









 Sleep quality – 
being able to 
have a restful 
sleep (CM only)
 Needing to rest 
or lie down 










smell, touch, or 
movement 









- Sleep quality – 
being able to 
have a restful 
sleep (CM only) 
- Needing to rest 
or lie down 




highlighted concern over 
the omission of the 




- Depressive mood 
- Vomiting / 
feelings of 
nausea 
All to be explored in 
consensus meeting (for 















 Satisfaction with 
treatment 
MEDICATION USE
Voting: Proposed domain 
REJECTED (values < 70%) 
Qualitative feedback 
highlighted the importance 
of a domain that was not 
just focused on medication 
use.  
NOTE: Voting on sub-group 
discrepancies (Table R3b) 
supported the inclusion of 
‘Treatment Satisfaction’ as 
a domain within the EM 




SATISFACTION’ is explored 
in consensus meeting for 
both EM and CM 
a. 
b. 







 Trigger factors – 
the ability to 
SELF-MANAGEMENT
- Ability to 
effectively 
a. 95.7% 85.7% 90.9% 
N/A N/A N/A 
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Qualitative feedback – 
proposed a more positive 
definition: 
















partners in their 
migraine 
treatment 
b. 91.3% 81.0% 86.4%
Footnote: 
Participants were invited to vote (Yes/No): a. Are you happy with the grouping of prioritised domains (Yes/No)? ; b. Are you happy with 
the proposed ‘meaningful’ domain and definition (Yes/No)? 
N/A: Not applicable. Panellists did not vote in this domain.  
Six of the seven domains for chronic migraine were retained (>73% across sub-panels; >80% 
combined) (Table 3). ‘Medication Use’ was rejected (<70%), and a redefining as ‘Treatment 
Satisfaction’ proposed. Qualitative feedback also highlighted the omission of ‘visual disturbances’ 
from ‘Associated Symptoms’, and the movement of ‘Sleep Quality’ to ‘Usual Activities’.  
For both episodic and chronic migraine, qualitative feedback highlighted the importance of 
communication difficulties within cognitive function; further consideration of vomiting/nausea, 
fatigue and depressive mood as additional ‘Associated Symptoms’; and unpredictability and ability to 
uphold usual commitments within ‘Usual Activities’. Further clarification of the concept of ‘Overall 
Health’ – for example, general or migraine-specific health, was proposed and adoption of a 
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standardised definition of ‘adverse events’ (Common Terminology Criteria for Adverse Events 
(CTCAE) 28. 
The process defined seven core domains common to episodic and chronic migraine (Table 3). 
Additionally, episodic migraine included ‘self-management’.  
Stage 2: Core Measurement Set 
 International expert panel face-to-face meeting 
The one-day meeting took place at Warwick University in December 2018. Seven patients (three 
with episodic migraine and four with chronic migraine) and seven healthcare 
professionals/researchers (two doctors, two nurses, one physiotherapist, two measurement experts) 
participated from two countries (UK, Portugal). Ten core group members, including two patient 
research partners (GP, BB), attended. 
Pain – was re-defined as migraine-specific pain and endorsed as an inner core domain for 
episodic and chronic migraine (>70%) (Table 4; Figure 2). Based on review of existing measures and 
group discussion voting supported recommendation of the 11-point numerical rating scale (NRS) for 
assessing pain intensity 29 and number of headache/migraine days per month for pain frequency  1, 
22. Due to the complexities around the concepts of headache and migraine, it was recommended 
that the specific terminologies should be defined by individual studies.  
Table 4. Consensus meeting: results from small and large group discussions and voting. 
Domain Small group  Large group  Final decision a 
Pain Domain 
Voting supported inclusion of 
Pain for EM and CM (>70%) 
Three aspects of Pain included:  
 intensity (11/11) 
 frequency (10/11)  
 duration (8/11) 
Proposed domain refinement to 
‘Migraine-specific Pain’ 
Measurement 
Voting for individual options did 
not exceed 70% 
Preferred assessments: 
Intensity: 11-point NRS (55%) 
Frequency: Number of 
headache/migraine days (64%) 
Duration: Cumulative hours per 
28-days of moderate/severe 
pain (55%) 
Domain 
INNER core: Migraine-specific 
pain (no further voting 
required) 
Measurement 
Pain intensity: 11-point NRS 
(80%) 
Pain frequency: Number of 
headache/migraine days 
(>70%) 
Pain duration: No consensus. 
Proposed that daily capture 
(using paper or electronic diary) 
or retrospective capture using a 
questionnaire may not be 
feasible for all trials.  
Voting: MIDDLE circle (89%) 
Domain – both EM and CM 
INNER core : Migraine-specific 
pain 
Components: intensity and 
frequency 
Measurement
Pain intensity – 11-point NRS 
(anchors ‘no pain’ and ‘pain as 
bad as you can imagine’) 
Pain frequency  
 number of headache / 
migraine days 
Pain Duration: MIDDLE circle: 
important but not feasible for all 
trials / research studies 
Overall 
Health 
Domain Domain Domain – both EM and CM 
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Voting supported redefining 
domain as Migraine-specific 
Quality of Life (73%) 
Measurement 
Migraine Functional Impact 
Questionnaire (72%) 
INNER core: Migraine-specific 
Quality of Life (no further 
voting required) 
Measurement 
Migraine Functional Impact 
Questionnaire  
INNER core: Migraine-specific 
Quality of Life  
Measurement 





Voting supported the rejection 
of adverse events from the core 





supported. Should be captured 
as part of good clinical practice 
guidance. 





No consensus on the inclusion 
(46%) / exclusion (54%) of self-
management. Participants 
considered it to be important to 
both EM and CM, but requiring 
greater conceptualisation 
before it can be accurately 
measured 
Domain 
Group confirmed the 
importance of self-
management for both EM and 
CM, but agreed that the lack of 
conceptualisation and method 
of assessment prevented 
inclusion in the COS.  
Voting: RESEARCH AGENDA 
(73%) 
Domain and measurement – 
both EM and CM 
OUTER circle - Research Agenda: 





Voting supported the rejection 
of cognitive function as a 
separate core domain (70%) 
But participants supported 




The importance of cognitive 
function was supported and the 
potential for it to be captured 
with migraine-specific quality 
of life proposed.  
Not included as a separate core 
domain for EM or CM. 
Cognitive function is included 
within the new domain 
‘Migraine-specific Quality of Life’ 




No consensus on the inclusion 
(50%) / exclusion (50%) of 
associated symptoms. 
Participants discussed the 
importance of a wide range of 
associated symptoms – but 
capture of all would not be 
feasible in all trials (and hence 
not core) 
Domain 
Participants recognised pain as 
an important ‘associated 
symptom’ and the inclusion of 
several additional associated 
symptoms within the new 
domain ‘MQoL’ (captured by 
the MFIQ).  
Capturing a larger number of 
associated symptoms, or 
specific additional symptoms - 
such as fatigue - should be 
study specific and not core. 
Voting: MIDDLE circle (100%) 
Domain and measurement – 
both EM and CM 
MIDDLE circle: important but not 





Voting supported the inclusion 
as a component of a new 
domain ‘MQoL’ (100%) 
Measurement 
Usual activities, as a component 
of MQoL to be assessed with 






Not included as a separate core 
domain for EM or CM. 
Usual activities is included within 
the new domain ‘Migraine-
specific Quality of Life’ and will 




Considered important – but no 
consensus on the inclusion 
Domain 
Group confirmed the 
importance of treatment 
Domain and measurement – 
both EM and CM 
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(64%) / exclusion(36%) of 
treatment satisfaction due to 
need for greater clarity 
satisfaction for both EM and 
CM, but agreed that the lack of 
conceptualisation and method 
of assessment prevented 
inclusion in the COS 
Voting: RESEARCH AGENDA 
(100%) 
OUTER circle - Research Agenda: 
important but requiring further 
study 
Footnote: a Core ‘inner’ circle: domain is unambiguous with an acceptable method of assessment; Middle circle:
domain is important, but not feasible for all preventative trials and research studies; Outer circle: domain is 
important, but requires further study (research agenda) – e.g. lacks conceptual clarity or method of 
assessment. 
Overall health – was re-defined as ‘migraine-specific quality of life’ (MSQoL), endorsed as an 
inner core domain for both episodic and chronic migraine (Table 4; Figure 2). Presented with 
evidence for generic and migraine quality of life measures, participants preferred the Migraine 
Functional Impact Questionnaire (MFIQ) 2, 30. The four domain scores of the MFIQ address several 
key concepts highlighted throughout the COSMIG process – including usual activities, physical, 
cognitive, social, and emotional function. It also provides a global item score for usual activities.   
Pain duration and associated symptoms were both judged as important, but not feasible for 
inclusion in all trials/research studies and placed in the middle circle (Table 4; Figure 2).  
Self-management and Treatment satisfaction – were both considered important for both 
episodic and chronic migraine, but lack of conceptualisation and assessment supported their 
placement on the research agenda (outer circle) (Table 4; Figure 2). 
Cognitive function and Usual activities were both rejected as independent core domains but 
proposed as important components of migraine-specific quality of life (Table 4).  
Adverse events – was rejected as a core domain, with the proposition that such reporting 
should be part of good clinical practice guidance (Table 4; Figure 2). 
The result was a two domain Core Outcome Set for both EM and CM (COSMIG) (Table 4; Figure 2):  
1) Migraine-specific pain: intensity assessed with the 11-point NRS and frequency as the 
number of headache/migraine days over a specified period; and  
2) Migraine-specific quality of life – assessed with the MFIQ 30. 
Discussion  
The COSMIG process has identified two core domains - pain and migraine-specific quality of life – that 
are recommended as part of a priori-designated outcomes in future preventive intervention clinical 
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trials for both episodic and chronic migraine. Pain assessment should include both intensity measured 
with an 11-point NRS, and frequency assessed as the number of headache/migraine days per 28 days. 
Migraine-specific quality of life should be assessed with the Migraine Functional Impact Questionnaire 
(MFIQ) 30. Complex concepts around headache and migraine meant that participants in the consensus 
meeting were not able to make recommendations for the phrasing of questions on pain severity (e.g., 
worst, average or typical) or the definition of a migraine/headache day. Thus, the specific 
terminologies should be defined, and reported, by the needs of individual studies. Likewise, the 
specific timing of assessments should be driven by the requirements of the study.  
Participants in the consensus meeting preferred the MFIQ over other measures of migraine-related 
quality of life such as the Migraine Specific Quality-of-Life Questionnaire MSQv2.1 and the 6-item 
Headache Impact Test (HIT-6) because participants, in particular patient participants, felt its domains 
best reflected the impact migraine has on people’s lives. This matches the aims of the original 
developers who specifically sought to address gaps in existing patient reported outcomes 31. A licence 
is needed to use the MFIQ available from Legal@evidera.com. The owners advise us that it will be 
available free of charge for non-commercial research (email Evidera 15 May 2020, personal 
communication). Pain duration and associated symptoms are important but are not considered core. 
How to assess self-management and treatment satisfaction requires further research before 
recommendations can be made. 
Our recommendation to include a reduction in the severity (intensity) and frequency in migraine 
pain is further supported by a recent modified-Delphi study conducted in the US, which sought to 
identify outcomes for value-based contracting for migraine medications.32 However, a Delphi study 
of experts (N=12) published after our work was completed focussed on establishing the most useful 
outcome measures, specifically for non-pharmacological interventions for migraine, identified the 
Migraine Disability Assessment (MIDAS) followed by the HIT-6 as preferred outcomes.33 Our 
empirical work does not support this prioritisation of outcome measures, 2,34
The COSMIG recommendations contrast with previous guidance for trials of prophylaxis in chronic 
migraine that recommend a single primary outcome derived from headache/migraine days. Patient-
reported headache-related quality of life appears last in order of the secondary outcomes1 and 
guidelines for trials of prophylaxis in episodic migraine do not include quality of life as an outcome 13. 
Informed by current good practice guidance in core outcome set development 9, 14, this study included 
international participation from patient and professional panellists in an on-line Delphi study and a 
subsequent face-to-face meeting. All data pertaining to the Delphi study were analysed both 
separately and combined to ensure that the views of sub-panels were clearly reported. This approach 
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highlighted the value placed upon patient-reported outcomes such as pain and quality of life by 
patients and health professionals. However, discrepancies pertaining to, for example, the importance 
of fatigue, unpredictability, emotional impact, and cognitive function were described. Such 
discrepancies have been reported in other long-term musculoskeletal conditions35 and more recently 
in a survey of health professionals and patients with COVID.36  Evidence of such discrepancies is a key 
driver for the suggestion that patients’ views are given at least equal wight to those of professionals 
in the process of core outcome set development.9  Incorporating outcomes that have resonance to all 
stakeholders can enhance trial relevance, providing valued information to inform decision-making in 
clinical practice and health policy settings. 
Whilst individuals from 14 countries were included in the Delphi study, participants from just two 
countries (England and Portugal) contributed to the face-to-face meeting. However, both the Delphi 
process and consensus meeting sought input from credible ‘experts’.17, 19 For patients, expert is 
defined by experience of living with chronic or episodic migraine, and for health professionals by their 
relative expertise in migraine-related research. The wide international involvement throughout the 
Delphi study improved international reach and helped ensure a wider relevance of the 
recommendations. We note that Delphi results are obtained from inviting experts to join a panel; as 
this eschews sampling, no inference should be made to any larger definable population. 
Active pre-engagement with potential participants in the Delphi study enabled targeted follow-up of 
non-responders in round one 37. We note that the participation rate of invited panellists is higher 
than reported in some other Delphi studies, where response rates between 30 and 40% have been 
reported.21  Moreover, a recent international Delphi study which sought to reach agreement on 
outcome measures for assessing the effectiveness of non-pharmacological interventions in migraine 
invited just 35 eligible researchers as subject experts, and four patients.33 Of the researchers, just 12 
agreed to participate, with 10 (28%) completing all three rounds. This suggests that the focus of our 
Delphi study resonated with panellists, and moreover, retention across subsequent rounds was high, 
with responses from both sub-panels exceeding 70%.  
More people with chronic migraine than with episodic migraine participated in the Delphi study, 
sub-panel responses were analysed separately for both panels. Seven of the eight prioritised 
domains were common to both episodic and chronic migraine; self-management was unique to 
episodic migraine. However, participants in the consensus meeting agreed that whilst poor 
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conceptualisation and lack of assessment option prevented its consideration as a core domain, self-
management was important for both episodic and chronic migraine. 
We relied on participant self-identification of diagnosis of episodic/chronic migraine. Any 
misclassification is unlikely to have any substantive impact on our findings. The study included a 
broad age-range of patient participants. Similarly, the healthcare professionals involved had a broad 
spectrum of experience in the care of patients with migraine and in migraine-related research.  
Working collaboratively with patient research partners throughout the research contributed to the 
crafting of ‘meaningful’ domains at each stage of the Delphi process, giving validity to the proposed 
lists 20. The initial Delphi questionnaire provided a comprehensive reflection of domains that might 
be assessed in chronic or episodic migraine. Additional domains were not proposed by participants 
in round one, supporting the comprehensiveness and relevance of content. Patient partners checked 
the comprehensibility and relevance of short-listed methods of assessment presented to 
participants in the consensus meeting, contributing to the debate and supporting lay participants 
during group discussions. All patient partners contributed to manuscript edits throughout the write-
up phase. 
The recommended COSMIG core set should be complemented by additional trial outcomes 
pertinent to the particular intervention being evaluated37. However, standardisation of core data 
collection is strongly advised to reduce the potential for systematic bias and enhance the quality of 
patient-reported outcomes data 8, 9. More work is now needed on how to evaluate the self-
management and treatment satisfaction domains.  
Through an international collaboration between patients, researchers, and health professionals, we 
have facilitated consensus on a Core Outcome Set for reporting on preventative intervention trials 
and research studies in adults with episodic or chronic MIGraine (COSMIG). We recommend that 
both pain (intensity and frequency) and migraine-specific quality of life are included as core 
domains. To support meaningful comparisons across studies, we recommend that pain intensity be 
assessed with a NRS 29 and frequency by determining the number of migraine days; migraine-specific 
quality of life should be assessed with the MFIQ 30. The timing of assessments should be determined 
by individual studies. 
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